Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Balch

Showing results (211-220 of 224) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patientsJ E Gershenwald, W Thompson, P F Mansfield, et al.
Journal of the American College of Surgeons|July 11, 1998
Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trialM K Wallack, M Sivanandham, C M Balch, et al.
Annals of Surgical Oncology|January 1, 1994
What is a surgical oncologist?C M Balch, K I Bland, M F Brennan, et al.
Annals of Surgical Oncology|April 13, 2000
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical TrialC M Balch, S Soong, M I Ross, et al.
Annals of Surgery|August 1, 1997
Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trialM K Wallack, M Sivanandham, K Ditaranto, et al.
Annals of Surgical Oncology|March 22, 2001
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomasC M Balch, S J Soong, T Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Prognostic factors for survival of patients treated systemically for disseminated melanomaO Eton, S S Legha, T E Moon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging systemA C Buzaid, M I Ross, C M Balch, et al.
Annals of Surgery|September 1, 1996
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and youngerC M Balch, S J Soong, A A Bartolucci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanomaO Eton, D D Kharkevitch, M A Gianan, et al.
Pageof 23

Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patientsJ E Gershenwald, W Thompson, P F Mansfield, et al.
Journal of the American College of Surgeons|July 11, 1998
Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trialM K Wallack, M Sivanandham, C M Balch, et al.
Annals of Surgical Oncology|January 1, 1994
What is a surgical oncologist?C M Balch, K I Bland, M F Brennan, et al.
Annals of Surgical Oncology|April 13, 2000
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical TrialC M Balch, S Soong, M I Ross, et al.
Annals of Surgery|August 1, 1997
Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trialM K Wallack, M Sivanandham, K Ditaranto, et al.
Annals of Surgical Oncology|March 22, 2001
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomasC M Balch, S J Soong, T Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Prognostic factors for survival of patients treated systemically for disseminated melanomaO Eton, S S Legha, T E Moon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging systemA C Buzaid, M I Ross, C M Balch, et al.
Annals of Surgery|September 1, 1996
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and youngerC M Balch, S J Soong, A A Bartolucci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanomaO Eton, D D Kharkevitch, M A Gianan, et al.
Pageof 23